Systemic Anti-Cancer Therapy Regimen Library
BR Adjuvant - Kadcyla [trastuzumab emtansine]
Treatment Overview
Cycles 1 to 14 - 21 days
After the initial dose of Kadcyla an observation period of at least 90 minutes post-infusion is recommended; if the initial dose of Kadcyla is well tolerated, subsequent doses may be administered over 30 minutes and an observation period of at least 30 minutes post-infusion is recommended.
Cycle details
Cycles 1 to 14 - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration | 1 | |
| Kadcyla | 3.6 mg/kg | intravenous | 1 | 90 minutes |
| domperidone | 10 mg Three times daily | oral administration | 1 |
After the initial dose of Kadcyla an observation period of at least 90 minutes post-infusion is recommended; if the initial dose of Kadcyla is well tolerated, subsequent doses may be administered over 30 minutes and an observation period of at least 30 minutes post-infusion is recommended.
Full details
Cycles 1 to 14 - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| ondansetron | 8 mg | oral administration |
Instructions:
ONE hour prior to chemotherapy. Alternative is dexamethasone 4 mg. |
|
| Kadcyla | 3.6 mg/kg | intravenous | 90 minutes |
Instructions:
Administer via a 0.22 micron in-line polyethersulfone (PES) filter. After the initial dose of Kadcyla an observation period of at least 90 minutes post-infusion is recommended; if the initial dose of Kadcyla is well tolerated, subsequent doses may be administered over 30 minutes and an observation period of at least 30 minutes post-infusion is recommended. |
| domperidone | 10 mg Three times daily | oral administration |
Instructions:
When required for nausea and/or vomiting. The choice of rescue antiemetic may be substituted to reflect institutional policy or individual patient characteristics. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Low |
References
2. Roche Products (New Zealand) Limited. Kadcyla New Zealand Data Sheet 11 May 2020. https://www.medsafe.govt.nz/profs/Datasheet/k/kadcylainj.pdf (Accessed 11 December 2020)
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.